Biogen Media |

All Press Releases

Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
8/1/16 7:30 am EDT
Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
7/21/16 7:00 am EDT
Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress
7/18/16 7:30 am EDT
SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency
7/17/16 9:05 pm EDT
Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
7/5/16 8:00 am EDT
Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
6/21/16 11:00 am EDT
Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016
6/20/16 4:01 pm EDT
New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio
6/9/16 7:08 am EDT
Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
6/7/16 7:30 am EDT
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program
6/1/16 11:45 am EDT

Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
8/1/16 7:30 am EDT
Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
7/21/16 7:00 am EDT
Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress
7/18/16 7:30 am EDT
SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency
7/17/16 9:05 pm EDT
Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
7/5/16 8:00 am EDT
Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
6/21/16 11:00 am EDT
Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016
6/20/16 4:01 pm EDT
New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio
6/9/16 7:08 am EDT
Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
6/7/16 7:30 am EDT
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program
6/1/16 11:45 am EDT